CARBIDOPA AND LEVODOPA 25 mg/1, 100 mg/1 TABLET, EXTENDED RELEASE
FDA Drug Information
Indications & Usage
INDICATIONS AND USAGE Carbidopa and levodopa extended-release tablets are indicated in the treatment of Parkinson's disease, post-encephalitic parkinsonism, and symptomatic parkinsonism that may follow carbon monoxide intoxication or manganese intoxication.
Important Warnings
WARNINGS When patients are receiving levodopa without a decarboxylase inhibitor, levodopa must be discontinued at least twelve hours before carbidopa and levodopa extended-release tablets are started. In order to reduce adverse reactions, it is necessary to individualize therapy. See DOSAGE AND ADMINISTRATION section before initiating therapy. Carbidopa and levodopa extended-release tablets should…
Source: FDA. For professional use only. Not a substitute for prescribing information.
Other CARBIDOPA AND LEVODOPA NDC Codes
Wholesale and compliance resources
Order NDC 62756-0461-88 at Wholesale
Create a free Premier Pharma account to unlock live wholesale pricing and place orders with same-day fulfillment and full DSCSA T2 documentation (TI + TS).